Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

Showing session: reset

Randomized Controlled Trials and Antiretroviral Resistance

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9
First-Line RAL + DRV/r Is Non-Inferior To TDF/FTC + DRV/r: The NEAT001/ANRS143 Randomised Trial
François Raffi
University Hospital, Nantes, France
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir With FTC/Tenofovir: ACTG 5257
Raphael J. Landovitz
Center for Clinical AIDS Research & Education, University of California Los Angeles, Los Angeles, CA, United States
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Attachment Inhibitor Prodrug BMS-663068 in ARV-Experienced Subjects: Week 24 Analysis
Jacob Lalezari
Quest Clinical Research, San Francisco, CA, United States
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Sensitive Screening Reveals Widespread Underestimation of Transmitted HIV Drug Resistance
Jeffrey A. Johnson
Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Transmitted HIV-1 Drug Resistance Between Partner-Pairs
Lisa M. Frenkel
University of Washington, Seattle, WA, United States and Seattle Children's Hospital, Seattle, WA, United States
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Silent Mutations in HIV-1 Subtype B Reverse Transcriptase Selected by ART Restore Viral Fitness
Sushama Telwatte
Centre for Biomedical Research, Burnet Institute, Melbourne, Australia and Department of Microbiology, Monash University, Melbourne, Australia
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Reduced In Vivo Replicative Capacity of Drug-Resistant SHIV During Acute Infection
J. Gerardo Garcia-Lerma
Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results
David Margolis
GSK, RTP, NC, United States
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
Safety and Antiviral Effect of MK-1439, A Novel NNRTI (+FTC/TDF) in ART-Naive HIV-Infected Patients
Javier O. Morales-Ramirez
Clinical Research Puerto Rico, San Juan, Puerto Rico
from CROI 2014 on March 5, 2014 10:00 AM-12:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9